These results highlight the advantages of AlloCAR70-NKT cells as a fratricide-free, exhaustion-resistant, and scalable off-the-shelf cellular therapy for targeting CD70-expressing cancers such as RCC, without the need for CD70 knockout engineering (Figure 2J).43 This evidence concerns the gene CD70 and renal cell carcinoma.